Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck

 
• By Bridget Silverman

The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker

brick wall falling down (Alamy)
Recent review setbacks are a reminder that breakthrough designations involve breaking things. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers